Provided By GlobeNewswire
Last update: Nov 4, 2024
SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy’s Laboratories Ltd.
Read more at globenewswire.comNASDAQ:DERM (5/30/2025, 8:00:01 PM)
8.06
-0.01 (-0.12%)
1.89
-0.06 (-3.08%)
Find more stocks in the Stock Screener